Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2019; 11(7): 551-566
Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.551
TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer
Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, Georgia Vourli, George Peros, Iordanis Papadopoulos, Ioannis Panayiotides, Anna Koumarianou
Anastasios Ntavatzikos, Anna Koumarianou, Hematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Athens 12462, Greece
Aris Spathis, Department of Cytopathology, National and Kapodistrian University of Athens, Medical School, “ATTIKON” University Hospital, Athens 12462, Greece
Paul Patapis, Nikolaos Machairas, 3rd Department of Surgery, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Athens 12462, Greece
Georgia Vourli, Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece
George Peros, Iordanis Papadopoulos, Department of Surgery, Medical School, National and Kapodistrian University of Athens, Evgenideio Therapeutirio S.A., “I AGIA TRIAS”, Athens 11528, Greece
Ioannis Panayiotides, 2nd Department of Pathology, University of Athens, Medical School, “ATTIKON” University Hospital, Athens 12462, Greece
Author contributions: Ntavatzikos A, Spathis A, Panayiotides I and Koumarianou A designed the research; Ntavatzikos A, Patapis P, Spathis A and Koumarianou A collected the data; Ntavatzikos A, Spathis A and Panayiotides I performed the research; Ntavatzikos A, Patapis P, Spathis A and Koumarianou A analyzed the data; Ntavatzikos A and Koumarianou A wrote the paper; Panayiotides I and Papadopoulos I offered the technical or material supports; Ntavatzikos A, Spathis A and Koumarianou A drafted the manuscript; all authors critically revised the manuscript for important intellectual content.
Supported by Kapodistrias, National and Kapodistrian University of Athens, No. 70/3/8006 (Pythagoras II, EPEAEK II, GSRT) and No. 70/3/9114; Spathis A was supported during data collection from No. 70/3/8462 [PENED - European Social Fund (75%) and the Greek Ministry of Development-GSRT (25%)].
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board and Ethical Committee of University General Hospital Attikon, Athens, Greece.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Anastasios Ntavatzikos, MD, Research Scientist, Hematology-Oncology Unit, 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Rimini 1, Haidari, Athens 12462, Greece. dmaal2@yahoo.gr
Telephone: +30-210-5831687 Fax: +30-210-5326446
Received: March 14, 2019
Peer-review started: March 15, 2019
First decision: April 16, 2019
Revised: April 30, 2019
Accepted: June 12, 2019
Article in press: June 13, 2019
Published online: July 15, 2019
Core Tip

Core tip: There is a need to identify patients with colorectal cancer (CRC) who may benefit from adjuvant chemotherapy. We investigated the survival in 130 patients with stage II-III CRC treated with adjuvant chemotherapy based on thymidylate synthase (TYMS) gene polymorphisms, KRAS and BRAF status. We found that TYMS polymorphisms and BRAF status associate independently with the survival outcomes. Prospective validating studies are required.